Critical Review: Ainos (NASDAQ:AIMD) and Amarillo Biosciences (OTCMKTS:AMAR)

Amarillo Biosciences (OTCMKTS:AMAR) and Ainos (NASDAQ:AIMD) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Amarillo Biosciences and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarillo Biosciences	-41,453.98%	N/A	-574.29%
Ainos	-11,912.10%	-217.50%	-67.87%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amarillo Biosciences and Ainos, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarillo Biosciences	0	0	0	0	0.00
Ainos	1	0	0	0	1.00

Given Amarillo Biosciences’ higher probable upside, research analysts plainly believe Amarillo Biosciences is more favorable than Ainos.

Valuation and Earnings

This table compares Amarillo Biosciences and Ainos”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A
Ainos	$13,600.00	770.98	-$14.77 million	($2.52)	-0.56

Amarillo Biosciences has higher revenue and earnings than Ainos.

Risk & Volatility

Amarillo Biosciences has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.